Aripiprazole
Product Images NDC 68151-4459

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68151-4459). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (68151 4459)

Label Image (68151 4459)
FDA Label Image

Figure 3 (Aripiprazole 3figure)

Figure 3 (Aripiprazole 3figure)
FDA Label Image

Figure 1 (Aripiprazole Figure1)

Figure 1 (Aripiprazole Figure1)
This is a table displaying the effect of various drugs on the concentration of aripiprazole. The drugs include CYP1A and CYP2D inhibitors, VP34 inducer, Gastric Acid Blockers, and Vlproate. The table shows the fold change and 90% CI for each drug, as well as the maximum concentration for certain drugs.*
FDA Label Image

Figure 2 (Aripiprazole Figure2)

Figure 2 (Aripiprazole Figure2)
FDA Label Image

Figure 4 (Aripiprazole Figure4)

Figure 4 (Aripiprazole Figure4)
This appears to be a partial table of data related to pharmacokinetics (how drugs are processed by the body) of a drug called "Arpiprazole" on special populations, such as those with hepatic (liver) or renal (kidney) impairment. It also indicates the effect of age, gender, and metabolizer status on the drug's concentration in the body. However, without more context or a complete table, it is difficult to understand the full implications of these findings.*
FDA Label Image

Figure 5 (Aripiprazole Figure5)

Figure 5 (Aripiprazole Figure5)
FDA Label Image

Figure 6 (Aripiprazole Figure6)

Figure 6 (Aripiprazole Figure6)
This appears to be a graph or table showing the proportion of subjects with relapse for a drug called "Arpiprazole" compared to a placebo, with the number of subjects at risk listed below. The x-axis appears to show the number of days from randomization. No further information is available.*
FDA Label Image

Structure (Aripiprazole Str)

Structure (Aripiprazole Str)
FDA Label Image

Trigen Laboratories Llc (Aripiprazole Trigen)

Trigen Laboratories Llc (Aripiprazole Trigen)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.